NEW YORK (GenomeWeb News) – Knome today announced the start of its early access program for knomeClinic, a software suite for the interpretation of human genomes for biological relevance.
The software is designed to help medical researchers and clinicians interpret the human genome, and those accepted into the early access program will receive installation priority, access to pilot programs, and pre-release prototypes, Knome said. They also will have the "ability to influence knomeClinic's feature set upon general release," the Cambridge, Mass.-based firm added.
Upon broad commercialization, knomeClinic will consist of kGAP, a robust, scalable, and extensible informatics and annotation platform that serves as the technical foundation for knomeClinic's desktop interpretation-support applications; desktop interpretation support applications that allow researchers and clinicians to identify variants, genes, and pathways that underlie disease and tumor growth; a knowledge database of reference data curated by Knome; and curation applications that allow researchers and clinicians to curate and prioritize genotype-phenotype associations.
Martin Tolar, CEO of Knome, said in a statement, "The shift to integrate whole genome information into clinical diagnosis and patient management is evolving rapidly, driven by steadily falling sequencing costs and improved understanding of actionable genetic data. With the launch of our early access program for knomeClinic, we are excited to begin collaborating with top-tier medical institutions in order to ensure that our software is optimized for the needs of clinical genomics and expectations of our initial partners."